ArticleAmerican journal of clinical and experimental immunology2026

Targeting cannabinoid receptor 1 for multiple sclerosis: molecular docking and dynamic insights of berberine and curcumin as potential therapeutic agents.

No numbers read from the abstract.

Not cited yet